Clinical Trial Update: Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Cancer: A Multicenter Study [Phase 2]

View source ↗

Summary

A Phase 2 multicenter trial evaluating perioperative tislelizumab combined with nab-paclitaxel for muscle-invasive urothelial bladder cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle-invasive Bladder Cancer
• Urothelial Carcinoma

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Tianjin Medical University Second Hospital | Conditions: Muscle Invasive Bladder Cancer Urothelial Carcinoma | Phase 2 | Status: UNKNOWN